Tyra Biosciences (TYRA) stock
Follow TYRA's trial news. Pro members can get an alert when Tyra Biosciences files news, and see its trials, share raises, and its CEO's filings.
What's next for TYRA, and how long its cash lasts
From Tyra Biosciences’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2H 2028 (8-K, Aug 4).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Sep 14, 2026)
Insiders
Director Rehan Verjee bought 972 shares on Sep 9. 3 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 26% in 3 months, 17% under its 50-day average.
Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over two years
4 more things pulling TYRA's score down, for Pro members
What's next
Expected to report Wed Nov 4, after the close
After its last 4 reports it closed -4.8% on average, higher 2 of 4 times.
What would turn TYRA's score around: 8 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
TYRA has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1436.8
- MACD (12, 26, 9)Below signal
- 50-day average$26.09
- 200-day average$30.52
- ADX 1417.1
- Support$20.07
- Resistance$22.82
- Bollinger Bands (20, 2)Inside
- Volume0.6x
How TYRA ranks in Biotech
TYRA is #243 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
TVTXOpen for its score
TWSTOpen for its score
UNCYOpen for its score
UPBOpen for its score
TYRA1/14-6
When does TYRA report earnings, and what happens after?
Expected to report Wed Nov 4, after the close (in 33 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 4, 2026After close | After close | -10.8% | -21.0% | -22.6% |
| May 13, 2026Before open | Before open | 0.0% | +3.8% | -3.1% |
| Mar 2, 2026After close | After close | -3.4% | +1.5% | +3.8% |
| Nov 5, 2025After close | After close | -0.6% | -3.6% | +4.5% |
Who is trading TYRA
TYRA insider trades
One insider bought $20K across 1 filing in the last 6 months. No open-market sales on record. The newest:
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of TYRA's score, with the points and the reason
- All 14 checks on TYRA and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on TYRA
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.